Zacks Investment Research downgraded shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) from a hold rating to a sell rating in a report issued on Friday morning.

According to Zacks, “Integra Lifesciences Holdings Corporation operates in the highly competitive surgical implants and medical instruments market. In the recently reported second quarter of 2016 gross margin contracted while selling, general and administrative expenses shoot up. Going forward higher burden of research and development expenditure is also expected. Growth would depend on faster ramp up of new products like Omnigraft. Also, it is worth noting that Integra’s 2016 organic revenue outlook considers a more challenging selling environment overseas, in countries such as Brazil, Mexico and China. Finally foreign exchange headwinds would continue to be a threat. Thus we would advise investors not to take any position in Integra Lifesciences for the near term.”

Several other equities research analysts have also recently commented on the company. Oppenheimer Holdings Inc. restated an outperform rating and issued a $93.00 target price on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, October 5th. TheStreet cut Integra LifeSciences Holdings Corp. from a buy rating to a hold rating in a research note on Friday, September 30th. Jefferies Group reiterated a buy rating and set a $95.00 price objective on shares of Integra LifeSciences Holdings Corp. in a research note on Tuesday, September 27th. Argus upped their price objective on Integra LifeSciences Holdings Corp. from $90.00 to $105.00 and gave the stock a buy rating in a research note on Friday, September 23rd. Finally, Piper Jaffray Cos. reiterated an overweight rating and set a $94.00 price objective (up previously from $86.00) on shares of Integra LifeSciences Holdings Corp. in a research note on Sunday, August 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $88.25.

Analyst Recommendations for Integra LifeSciences Holdings Corp. (NASDAQ:IART)

Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 1.37% during midday trading on Friday, reaching $84.19. 91,987 shares of the company’s stock were exchanged. Integra LifeSciences Holdings Corp. has a 12 month low of $54.75 and a 12 month high of $88.86. The company has a market cap of $3.15 billion, a P/E ratio of 347.89 and a beta of 0.43. The company has a 50 day moving average price of $85.40 and a 200 day moving average price of $77.43.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last released its earnings results on Thursday, July 28th. The company reported $0.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.03. The firm had revenue of $249.30 million for the quarter, compared to analysts’ expectations of $243.17 million. Integra LifeSciences Holdings Corp. had a return on equity of 15.41% and a net margin of 0.79%. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 EPS. On average, equities analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 EPS for the current year.

In other Integra LifeSciences Holdings Corp. news, Director Raymond G. Murphy sold 2,600 shares of the company’s stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $86.64, for a total value of $225,264.00. Following the transaction, the director now directly owns 33,047 shares of the company’s stock, valued at approximately $2,863,192.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Peter J. Arduini sold 24,009 shares of the company’s stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $84.52, for a total value of $2,029,240.68. Following the completion of the transaction, the chief executive officer now directly owns 29,602 shares in the company, valued at $2,501,961.04. The disclosure for this sale can be found here. 22.00% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Societe Generale purchased a new position in shares of Integra LifeSciences Holdings Corp. during the second quarter worth approximately $106,000. First Manhattan Co. purchased a new position in shares of Integra LifeSciences Holdings Corp. during the second quarter worth approximately $135,000. BlackRock Inc. raised its position in shares of Integra LifeSciences Holdings Corp. by 137.2% in the first quarter. BlackRock Inc. now owns 2,016 shares of the company’s stock worth $136,000 after buying an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Integra LifeSciences Holdings Corp. by 718.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,454 shares of the company’s stock worth $196,000 after buying an additional 2,154 shares in the last quarter. Finally, Strs Ohio raised its position in shares of Integra LifeSciences Holdings Corp. by 107.1% in the second quarter. Strs Ohio now owns 2,900 shares of the company’s stock worth $231,000 after buying an additional 1,500 shares in the last quarter. 88.32% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Holdings Corp. Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Stock Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related stocks with our FREE daily email newsletter.